Réf. : HematoStat.net ; 1 (16) Makishima H, Saiki R, Nannya Y et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood (2023) 141 (5): 534–549. Résumé […]

Réf. : HematoStat.net ; 1 (15) Chen GL, Onstad L, Martin PJ et al. Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease. Haematologica Vol. 108 No. […]

Réf. : HematoStat.net ; 1 (14) Westin J, Davis RE, Feng L et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin […]

Réf. : HematoStat.net ; 1 (13) : R65 de Botton S, Montesinos P, Schuh AC, et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a […]

Réf. :HematoStat.net ; 1 (13) : R64 Guillet S, Loustau V, Boutin E, et al. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood. 2023 141(1):11-21. Résumé de l’article : Un total […]

Réf. :HematoStat.net ; 2 (12) : R63 Brink M, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, et al. Impact of etoposide and ASCT on survival among […]

Réf. :HematoStat.net ; 2 (12) : R62 Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult […]

Réf. :HematoStat.net ; 2 (12) : R61 Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Bhat SA, Gambril J, Azali L, Chen ST, Rosen L, Palettas M, et al. […]

Réf. :HematoStat.net ; 2 (12) : R60 Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol […]

Réf. :HematoStat.net ; 2 (12) : R59 Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Döhner H, Wei AH, Roboz […]